George Clinical (CEO James Cheong) participated in ‘BIO KOREA 5’ held at COEX, Seoul for three days from May 10 (Wed) to 12 (Fri).
George Clinical is a world-class clinical trial agency (CRO) founded in Australia, operating based on over 20 years of experience and scientific expertise. More than 38 people manage 450 branches located in the United States, Asia Pacific, and Europe, and provide a variety of clinical trial services at all stages from registration to post-marketing trials.
In this exhibition, it showcased its capabilities as a clinical trial agency to Korean companies that wish to conduct clinical trials around the world, mainly in the Asia Pacific region. George Clinical’s network, which has solid facilities and competent analysts, supports fast start-up schedules and high-level data to boost Korean companies that want to conduct clinical trials in an advantageous position from the initial analysis stage.
As a full-service CRO, it was pointed out that it has a network of key opinion leaders (KOLs) in a wide range of therapeutic areas, as well as early analysis expertise, as well as in-depth expertise in oncology, cardiovascular disease, kidney disease, and metabolic disease. He is also accredited by the Australian Genetic Control Authority (OGTR).
An official from George Clinic explained the background of participating in the exhibition, saying, “We wanted to create a place where participants in this exhibition could interact with related experts by developing a comprehensive service that can be provided throughout the Asia Pacific region, from the initial analysis stage to the monitoring stage of side effects.”
“We are pioneering CRO services with new technologies and partners that help select relevant oncology patients through biomarkers and facilitate clinical enrollment.”
Meanwhile, ‘BIO KOREA 18’, which celebrated its 2023th anniversary this year, was hosted by the Korea Health Industry Development Institute and Chungcheongbuk-do. BIO KOREA, which has been striving to improve the global status and sustainable growth of the Korean health industry since 2006, is solidifying its position as Korea’s representative biohealth international convention with the participation of world-class scholars and business experts every year. BIO KOREA 2023, in collaboration with companies related to the health industry such as domestic and foreign bio, pharmaceuticals, medical devices, cosmetics, and food, as well as interested companies and institutions such as consulting, academia, and related organizations, will be held through various programs such as conferences, business partnering, exhibitions, and investment fairs. It went ahead.
→ Go to the BIO KOREA 2023 news special page
